You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm has partnered with Illumina to use the Dragen Bio-IT informatics platform to help customers analyze data from the new Cancer Transcriptome Atlas panel.
The Cambridge, Massachusetts-based firm also said it tacked on $3 million to its Series B financing round for a total of $30 million.
The company plans to offer four new products by the end of the year, including four targeted transcriptomic panels and IHC compatibility for Visium.
The project has sequenced more than 1,700 individuals from across Asia to high coverage in order to bolster the representation of Asians in genomic research.
A study group eager to learn about genetic testing online was not won over by videos produced by academics without communication expertise.
The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.
The new system, called BODE 2, will launch at the end of this year and will replace the existing BODE for the analysis of "big omics" data for research.
Sequencing and other experiments on barcoded Plasmodium berghei mutant strains helped researchers narrow in on key metabolic pathways in the parasite's liver stage.
This report contains a quantitative, evidence-based scoring framework to help guide the evaluation of constitutional CNVs across clinical labs.
Northern California healthcare system NorthBay Healthcare will evaluate the platform's ability to improve the routine use of genetic testing.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.